AF
ABUS icon

Allworth Financial’s Arbutus Biopharma ABUS Stock Holding History

Allworth Financial’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4K Buy
2,159
+99
+5% +$435 ﹤0.01% 3688
2026
Q1 		$9.27K Buy
2,060
+17
+0.8% +$74 ﹤0.01% 3556
2025
Q4 		$9.83K Buy
2,043
+1,928
+1,677% +$8.67K ﹤0.01% 3278
2025
Q3 		$523 Sell
115
-304
-73% -$1.12K ﹤0.01% 4425
2025
Q2 		$1.29K Sell
419
-258
-38% -$857 ﹤0.01% 3885
2025
Q1 		$2.26K Buy
+677
New +$2.26K ﹤0.01% 3165
2023
Q3 		– Sell
-440
Closed -$1.01K – 3432
2023
Q2 		$1.01K Hold
440
– – ﹤0.01% 2732
2023
Q1 		$1.33K Hold
440
– – ﹤0.01% 2562
2022
Q4 		$1.02K Buy
+440
New +$1.05K ﹤0.01% 2468

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Allworth Financial's ABUS Position: Q2 2026 in Review

Allworth Financial increased its Arbutus Biopharma (ABUS) stake by 4.8% in Q2 2026, buying an estimated $435 and bringing the position to 2,159 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3688.

Allworth Financial first reported a position in ABUS in Q4 2022 and has held it in 9 quarters since. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Allworth Financial held 2,159 shares of Arbutus Biopharma worth $10.4K as of Q2 2026.
  • Allworth Financial bought 99 Arbutus Biopharma shares in Q2 2026, an estimated $435.
  • Arbutus Biopharma made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #3688 holding.
  • Allworth Financial first reported a position in Arbutus Biopharma in Q4 2022 and has held it in 9 quarters since.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.